CARsgen Therapeutics Holdings Ltd
HKEX:2171

Watchlist Manager
CARsgen Therapeutics Holdings Ltd Logo
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Watchlist
Price: 14.68 HKD -3.17%
Market Cap: 8.4B HKD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CARsgen Therapeutics Holdings Ltd stock under the Base Case scenario is 0.51 HKD. Compared to the current market price of 14.68 HKD, CARsgen Therapeutics Holdings Ltd is Overvalued by 97%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
0.51 HKD
Overvaluation 97%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

199.4
P/S
P/S
Price to Sales
199.4
vs History
39
vs Industry
3
Median 3Y
136
Median 5Y
0
Industry
6.7
Forward
5.9
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-5.6
Median 5Y
-6.2
Industry
22.3
Forward
-13.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-10.4
Median 5Y
-11.1
Industry
19.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-8
Industry
23.8
More Details
7.4
P/B
P/B
Price to Book Value
7.4
vs History
6
vs Industry
21
Median 3Y
2.3
Median 5Y
2.5
Industry
2.3
More Details
165.3
EV/S
EV/S
Enterprise Value to Sales
165.3
vs History
27
vs Industry
3
Median 3Y
79.8
Median 5Y
0
Industry
7.3
Forward
4.9
More Details
441.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
441.9
vs History
12
vs Industry
0
Median 3Y
0
Median 5Y
0
Industry
9.1
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
30
Median 3Y
-4.6
Median 5Y
-5.6
Industry
3.8
Forward
-12.3
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
28
Median 3Y
-4.3
Median 5Y
-5
Industry
3.6
Forward
-10.6
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
31
Median 3Y
-6.3
Median 5Y
-7.1
Industry
4.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
28
Median 3Y
-5.1
Median 5Y
-5.5
Industry
2.9
More Details
33.6
EV/IC
EV/IC
Enterprise Value to IC
33.6
vs History
12
vs Industry
17
Median 3Y
6.8
Median 5Y
8.1
Industry
4.3
More Details

Multiples Across Competitors

Competitors Multiples
CARsgen Therapeutics Holdings Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
CARsgen Therapeutics Holdings Ltd
HKEX:2171
8.4B HKD 199.4 -9.9 -9 -8.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 194 575.7 -172 027.5 -208 896.1 -206 512.4
US
Abbvie Inc
NYSE:ABBV
330B USD 5.9 77.9 15.5 23.3
US
Amgen Inc
NASDAQ:AMGN
158.1B USD 4.7 38.6 15.8 27.9
US
Gilead Sciences Inc
NASDAQ:GILD
133.6B USD 4.6 278.4 10.9 13.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.9B USD 11.1 -227.7 24.9 26
US
Epizyme Inc
F:EPE
94.1B EUR 1 946.4 -496.7 -540.9 -526.4
AU
CSL Ltd
ASX:CSL
118.7B AUD 4.7 25.9 16.1 20.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
62.9B USD 4.4 14.2 8.7 9.7
US
Seagen Inc
F:SGT
39.3B EUR 18.7 -57.5 -61.9 -55.8
NL
argenx SE
XBRU:ARGX
31.1B EUR 15.6 41 300.7 -2 215.5
P/S Multiple
Revenue Growth P/S to Growth
CN
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Average P/S: 3 290 617.4
199.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
36 194 575.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.6
3%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.1
10%
1.1
US
E
Epizyme Inc
F:EPE
1 946.4
N/A N/A
AU
CSL Ltd
ASX:CSL
4.7
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.4
7%
0.6
US
S
Seagen Inc
F:SGT
18.7
30%
0.6
NL
argenx SE
XBRU:ARGX
15.6
37%
0.4
P/E Multiple
Earnings Growth PEG
CN
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Average P/E: 79.3
Negative Multiple: -9.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -172 027.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.9
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
38.6
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
278.4
187%
1.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -227.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -496.7 N/A N/A
AU
CSL Ltd
ASX:CSL
25.9
16%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
14.2
12%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.5 N/A N/A
NL
argenx SE
XBRU:ARGX
41
26%
1.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Average EV/EBITDA: 56.1
Negative Multiple: -9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 896.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
15.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
7%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.9
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -540.9 N/A N/A
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.7
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.9 N/A N/A
NL
argenx SE
XBRU:ARGX
300.7
166%
1.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
CARsgen Therapeutics Holdings Ltd
HKEX:2171
Average EV/EBIT: 20.1
Negative Multiple: -8.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -206 512.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.3
28%
0.8
US
Amgen Inc
NASDAQ:AMGN
27.9
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
13.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26
15%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.4 N/A N/A
AU
CSL Ltd
ASX:CSL
20.1
14%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.7
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.8 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 215.5 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 244,300+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.